Trial site
Jiamusi Cancer Hospital
Jiamusi, Heilongjiang 154007, ChinaNot linked to an institution yet
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 1/22 trials
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Recruiting2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Daiichi Sankyo4 trials
- Amgen2 trials
- BioNTech SE2 trials
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 trial
- Shanghai Henlius Biotech1 trial
Running trials
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966· Phase 1/2· Daiichi Sankyo· Source
Active, not recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· Phase 3· Amgen· Source
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· Phase 3· BioNTech SE· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Active, not recruiting
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768· Phase 1/2· Daiichi Sankyo· Source
Active, not recruiting
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· Phase 3· Amgen· Source
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776· Daiichi Sankyo· Source
Contact: Principal Investigator
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error